Effect of rosiglitazone on progression of atherosclerosis: Insights using 3D carotid cardiovascular magnetic resonance

Journal of Cardiovascular Magnetic Resonance

Volumn 11, Issue 1, 2009, Pages

  Varghese, Anitha ^a,b   Yee, Michael S ^c,d   Chan, Cheuk F ^a,b   Crowe, Lindsey A ^a   Keenan, Niall G ^a,b   Johnston, Desmond G ^c,d   Pennell, Dudley J ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ANGINA PECTORIS; ARTERY WALL; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR MAGNETIC RESONANCE; CAROTID ARTERY; CAROTID ARTERY BIFURCATION; CAROTID ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; EDEMA; FEMALE; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THERAPY EFFECT; THREE DIMENSIONAL IMAGING; TREATMENT DURATION; VASCULAR DISEASE; BLOOD; CAROTID ARTERY DISEASE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CAROTID ARTERIES; CAROTID ARTERY DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349565579     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-11-24     Document Type: Article

References (46)

1. Global and societal implications of the diabetes epidemic. P Zimmet KG Alberti J Shaw, Nature 2001 414 782 87 10.1038/414782a 11742409
2. Diabetes and the heart. AH Barnett G O'Gara, London: Churchill Livingstone 2003
3. Diabetes mellitus and diabetes-associated vascular disease. D Kirpichnikov JR Sowers, Trends Endocrinol Metab 2001 12 225 30 10.1016/S1043-2760(01)00391-5 11397648
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998 352 837 53 10.1016/S0140-6736(98)07019-6 9742976
5. Thiazolidinediones. H Yki-Jarvinen, N Engl J Med 2004 351 1106 18 10.1056/NEJMra041001 15356308
6. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 368 1096 105 10.1016/S0140-6736(06)69420-8 16997664
7. PPARs: therapeutic targets for metabolic disease. JP Berger TE Akiyama PT Meinke, Trends Pharmacol Sci 2005 26 244 51 10.1016/j.tips.2005.03.003 15860371
8. For the GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. RB Goldberg DM Kendall MA Deeg JB Busse AJ Zagar JA Pinaire MH Tan MA Khan AT Perez SJ Jacober, Diabetes Care 2005 28 1547 54 10.2337/diacare.28. 7.1547 15983299
9. K Winkler I Friedrich MW Baumstark H Wieland W Marz, BJ Diab and Vasc Dis 2002 2 143 8 10.1177/14746514020020021301
10. Rosiglitazone Study 108 investi. MI Freed R Ratner SM Marcovina MM Kreider N Biswas BR Cohen JD Brunzell, Am J Cardiol 2002 90 947 52 10.1016/S0002-9149(02)02659-0 12398960
11. Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Z Levi A Shaish N Yacov H Levkovitz S Trestman Y Gerber H Cohen A Dvir R Rhachmani M Ravid D Harats, Diabetes Obes Metab 2003 5 45 50 10.1046/j.1463-1326.2003.00240. x 12542724
12. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. AC Calkin JM Forbes CM Smith M Lassila ME Cooper KA Jandeleit-Dahm TJ Allen, Arterioscler Thromb Vasc Biol 2005 25 1903 9 10.1161/01.ATV.0000177813.99577.6b 16020748
13. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. DJ Stocker AJ Taylor RW Langley MR Jezior RA Vigersky, Am Heart 2007 155 1 445
14. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. R Corti V Fuster ZA Fayad SG Worthley G Helft D Smith J Weinberger J Wentzel G Mizsei M Mercuri JJ Badimon, Circulation 2002 106 2884 7 10.1161/01.CIR.0000041255.88750.F0 12460866
15. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. B Hedblad A Zambanini P Nilsson L Janzon G Berglund, J Intern Med 2007 261 293 305 10.1111/j.1365-2796.2007.01767. x 17305652
16. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. ML Bots AW Hoes PJ Koudstaal A Hofman DE Grobbee, Circulation 1997 96 1432 7 9315528
17. Common carotid artery intima-media thickness and brain infarction: the Etude du Profil Genetique de l'Infarctus Cerebral (GENIC) case-control study: the GENIC Investigators. PJ Touboul A Elbaz C Koller C Lucas V Adrai F Chedru P Amarenco, Circulation 2000 102 313 8 10899095
18. Ultrsonographically assessed carotid morphology and the risk of coronary heart disease. JT Salonen R Salonen, Arterioscler Thromb 1991 11 1245 9 1911709
19. The role of carotid arterial intima-media thickness in predicting clinical coronary events. HN Hodis WJ Mack L LaBree RH Selzer CR Liu CH Liu SP Azen, Ann Inter Med 1998 128 262 9
20. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. G Geroulakos DJ O'Gorman E Kalodiki DJ Sheridan AN Nicolaides, Eur Heart J 1994 15 6 781 5 8088266
21. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. JR Crouse III TE Craven AP Hagaman G Bond, Circulation 1995 92 1141 7 7648658
22. Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. M Kodama Y Yamasaki K Sakamoto R Yoshioka M Matsuhisa Y Kajimoto K Kosugi N Ueda M Hori, Thromb Res 2000 97 239 45 10.1016/S0049-3848(99)00168-1 10674411
23. Effects of ramipril and vitamin E on athersclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). E Lonn S Yusuf V Dzavik C Doris Q Yi S Smith A Moore-Cox J Bosch W Riley K Teo, Circulation 2001 103 919 25 11181464
24. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS). B Hedblad J Wikstrand L Janzon H Wedel G Berglund, Circulation 2001 103 1721 6 11282901
25. Regression of carotid and femoral intima-media thickness in familial hypercholesterolaemia: treatment with simvastatin. PRW De Sauvage Nolting E de Groot AH Zwinderman RJ Buirma MD Trip JJ Kastelein, Arch Intern Med 2003 163 1837 41 10.1001/archinte.163.15.1837 12912721
26. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. TJ Smilde S van Wissen H Wollersheim MD Trip JJ Kastelein AF Stalenhoef, Lancet 2001 357 577 81 10.1016/S0140-6736(00)04053-8 11558482
27. Interstudy reproducibility of 3D volume selective fast spin echo sequence for quantifying carotid artery wall volume in asymptomatic subjects. A Varghese LA Crowe RH Mohiaddin PD Gatehouse GZ Yang DN Firmin DJ Pennell, Atherosclerosis 2005 183 361 6 10.1016/j.atherosclerosis.2005.03.020 16285999
28. Interstudy reproducibility of three-dimensional volume-selective fast spin echo magnetic resonance for quantifying carotid artery wall volume. A Varghese LA Crowe RH Mohiaddin PD Gatehouse GZ Yang DM Nott JM McCall DN Firmin DJ Pennell, J Magn Reson Imaging 2005 21 187 91 10.1002/jmri.20249 15666396
29. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. R Corti ZA Fayad V Fuster SG Worthley G Helft J Chesebro M Mercuri JJ Badimon, Circulation 2001 104 249 52 10.1161/hc4001.097191 11457739
30. Evaluation of carotid artery wall volume measurement using novel semiautomated analysis software. A Varghese RD Merrifield LA Crowe SA Collins NG Keenan DN Firmin GZ Yang DJ Pennell, J Magn Reson Imaging 2006 24 1401 8 10.1002/jmri.20798 17096390
31. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. MR Langenfeld T Forst C Hohberg P Kann G Lubben T Konrad SD Fullert C Sachara A Pfutzner, Circulation 2005 111 2525 31 10.1161/01.CIR.0000165072.01672.21 15883215
32. The selective peroxisomal proliferators-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. R Corti JI Oscende JT Fallon V Fuster G Mizsei H Jneid SD Wright WF Chaplin JJ Badimon, J Am Coll Cardiol 2004 43 464 73 10.1016/j.jacc.2003.08.048 15013132
33. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. SE Nissen K Wolski, N Engl J Med 2007 356 2457 71 10.1056/NEJMoa072761 17517853
34. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. S Singh YK Loke CD Furberg, JAMA 2007 298 1189 95 10.1001/jama.298.10.1189 17848653
35. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. PD Horne SJ Pocock H Beck-Nielson R Gomis M Hanefeld NP Jones M Komajda JJV McMurray for the RECORD Study Group, N Engl J Med 2007 357 28 38 10.1056/NEJMoa073394 17551159
36. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes - the PERISCOPE randomized controlled trial. SE Nissen SJ Nicholls K Wolski R Nesto S Kupfer A Perez H Jure R De Larochellière CS Staniloae K Mavromatis J Saw B Hu AM Lincoff EM Tuzcu for the PERISCOPE Investigators, JAMA 2008 299 1561 1573 10.1001/jama.299.13.1561 18378631
37. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiological normal. JH O'Keefe Jr L Cordain WH Harris RM Moe R Vogel, J Am Coll Cardiol 2004 43 2142 6 10.1016/j.jacc.2004.03.046 15172426
38. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. SE Nissen EM Tuzcu P Schoenhagen T Crowe WJ Sasiela J Tsai J Orazem RD Magorien C O'Shaughnessy P Ganz for the Reversal of atherosclerosis with Aggressive Lipid lowering (REVERSAL) Investigators, N Engl J Med 2005 352 29 38 10.1056/NEJMoa042000 15635110
39. The effects of metformin on glycaemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. AC Robinson J Burke S Robinson DG Johnston RS Elkeles, Diabetes Care 1998 21 701 5 10.2337/diacare.21.5.701 9589227
40. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. SE Kahn SM Haffner MA Heise WH Herman RR Holman NP Jones BG Kravitz JM Lachin MC O'Neill B Zinman G Viberti, N Engl J Med 2006 355 2427 43 10.1056/NEJMoa066224 17145742
41. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. SE Nissen EM Tuzcu P Schoenhagen BG Brown P Ganz RA Vogel T Crowe G Howard CJ Cooper B Brodie CL Grines AN DeMaria for the REVERSAL Investigators, JAMA 2004 291 1071 1080 10.1001/jama.291.9.1071 14996776
42. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID Trial. SE Nissen SJ Nicholls I Sipahi P Libby JS Raichlen CM Ballantyne J Davignon R Erbel JC Fruchart JC Tardif P Schoenhagen T Crowe V Cain K Wolski Goormastic EM Tuzcu for the ASTEROID Investigators, JAMA 2006 295 1556 1565 10.1001/jama.295.13.jpc60002 16533939
43. Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia. E Trogan ZA Fayad VV Itskovich JGS Aguinaldo V Mani JT Fallon I Chereshnev EA Fisher, Arterioscler Thromb Vasc Biol 2004 24 1714 9 10.1161/01.ATV.0000139313.69015.1c 15256400
44. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. DP Tilden S Mariz G O'Bryan-Tear J Bottomly A Diamantopoulos, Pharmacoeconomics 2007 25 39 54 10.2165/00019053-200725010-00005 17192117
45. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. AM Lincoff K Wolski SJ Nicholls SE Nissen, JAMA 2007 298 1180 8 10.1001/jama.298.10.1180 17848652
46. Pioglitazone reduces neointima volume after coronary stent implanatation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. N Marx J Wöhrle T Nusser D Walcher A Rinker V Hombach W Koenig M Höher, Circulation 2005 112 2792 8 10.1161/CIRCULATIONAHA.105.535484 16246947